Dr. A Ramamurthy | Regenix Group
Did you know that advanced life-saving therapies will become available to millions of patients only when biosimilars hit the market? In many ways, biosimilars are doing for healthcare what smartphones did for technology – taking high-end innovation and making it affordable, scalable and accessible to the everyday person.
With the continued rise of chronic diseases including diabetes across the world, the biosimilar and biopharmaceutical industry is becoming one of the most important pillars of modern healthcare. However, it is also one of the most demanding and competitive industries in the world, where scientific precision, regulatory excellence, technological capability and long-term vision determine success.
Regenix Drugs Ltd, one of the companies spearheading this change, was started by Dr. A. Ramamurthy, a gold medallist from Madras University, who made the transition from a successful diabetologist to a visionary healthcare entrepreneur.
Dr Ramamurthy founded the Regenix Group in 2007 after a successful build and exit of a US FDA approved pharmaceutical venture to make advanced biosimilar therapies affordable and accessible. Today, the company operates a single, integrated healthcare ecosystem, combining biosimilar manufacturing, branded generics, diagnostics, pharmacies and hospital access on one platform.
Creating an Integrated Healthcare Ecosystem
The Regenix journey starts with a simple but powerful philosophy: “molecule to patient direct.” Regenix is not just another pharmaceutical company. Regenix has developed an integrated healthcare model which connects all processes in the healthcare value chain.
Today, the company’s branded generic business covers nearly 70% of India through specialized divisions in cardiology, diabetology, surgery, gastroenterology, neurology, obstetrics & gynecology and pediatrics.
On the biosimilar side, Regenix has received Market Authorization at its MEPZ facility for products such as Insulin Glargine, Insulin Regular, Insulin Mix and Liraglutide. Meanwhile, molecules such as Aspart and Semaglutide are in various stages of development.
This combination of manufacturing capability, clinical understanding and accessibility to the patients has enabled the organization to establish itself as a growing force in India’s biosimilar ecosystem.
From Diabetologist to Biopharma Entrepreneur
His experience as a diabetologist in clinical practice was a key driver for Dr Ramamurthy’s move to the biopharmaceutical industry. He saw the rapid rise of diabetes cases across India and recognized the urgent need for affordable, high-quality insulin therapies.
That realization expanded his view from clinical treatment to large-scale healthcare innovation.
He started his entrepreneurial journey in 1996 with the Grandix Pharmaceuticals Group, helping to build a strong branded generics company and a US FDA approved manufacturing facility. The venture was subsequently sold in 2006 for approx. USD 30 million.
But the road to biosimilars has proved to be a much longer and tougher journey.
Biosimilar development demands patience, technical expertise, substantial capital and regulatory discipline. It took Regenix nearly a dozen years to figure out the right way to make biosimilar insulin. A key milestone in this journey was the successful launch of Insulin Glargine in India and the global market in 2025.
Innovate with Thoughtful Implementation
For Dr Ramamurthy, innovation in biosimilars is not only about scientific advancement but also about faster, smarter and more efficient ways of delivering globally accepted therapies at affordable costs without compromising quality.
In just six years under his leadership, Regenix obtained Market Authorization for four biosimilars – a remarkable accomplishment in a highly regulated industry. During this period, the company also achieved WHO-GMP certification and a number of global registrations, while continuing to grow its biosimilar pipeline.
These milestones are a testament to a development strategy centered on operational discipline, scientific precision and execution excellence.
How to Overcome the Challenges of Biosimilar Development
The biosimilar industry is regarded as one of the most complicated segments of the pharmaceutical industry. Regenix faced some big challenges like capital intensive infrastructure requirements, technology acquisition, skilled manpower shortages, clinical trials and regulatory complexities and long gestation period.
The company took a very strategic and flexible approach to tackle these challenges.
Rather than putting significant resources into cell bank development in early phases, Regenix contracted out biosimilar drug substance development. This brought down development costs considerably and shortened timelines.
The organization also partnered with global biosimilar companies and technical consultants to enhance operational expertise and hasten manufacturing readiness.
One of the main challenges was the lack of locally available experience biosimilar technical manpower in Tamil Nadu. For that, Regenix sourced specialized talent from cities such as Bangalore and Mumbai, while building expertise internally.
The execution of clinical trials and regulatory approvals were managed in partnership with experienced centers and industry professionals to support the company in navigating one of the most difficult pathways in healthcare manufacturing.
Dedication to Quality and International Standards
Regenix has established robust systems for quality and regulatory compliance throughout the development and manufacturing process, in an industry where patient safety and product consistency are critical.
The company also has Building Management Systems (BMS) and digital monitoring controls to adhere to stringent quality standards and safety protocols. Every step of the process is closely monitored to ensure it is in line with Indian and international regulatory expectations.
Affordable doesn’t mean sacrificing quality with Regenix. The company’s vision is to deliver biosimilar therapies that are accepted globally and are affordable, while ensuring compliance with international manufacturing standards.
Research, Clinical Trials And Tech-Enabled Growth
Research, clinical trials and technological advances are the bedrock of the company’s innovation pipeline.
Clinical trials are required for efficacy, safety and biosimilarity to innovator molecules as well as for regulatory approvals. At the same time, the processes of modern development and technological platforms help to speed up the terms and become more efficient.
Regenix has managed this by combining scientific research with strategic execution, mitigating the developmental uncertainties typically inherent in the pharmaceutical R&D process.
Broadening Access to Affordable Diabetes Care
Dr Ramamurthy’s proudest achievement is perhaps the creation of a portfolio of insulin therapies, including insulin analogues, which provides clinicians with a wider range of treatment options and allows for more personalized diabetes care.
More importantly, these products are also improving access for patients who otherwise may not have been able to afford advanced therapies.
The worldwide health challenge of diabetes continues to grow and affordable biosimilars are expected to play a critical role in improving healthcare outcomes across emerging markets.
Staying Competitive in a Fast-Changing Industry
The biotechnology and biosimilar industry is fast moving, and companies need to be fast, flexible and constantly innovative.
Regenix has been focusing on bringing multiple biosimilars to market in shorter timeframes, whilst maintaining a healthy pipeline of products to come. Such an aggressive yet disciplined expansion strategy has helped the company to stay competitive in Indian and international market.
Collaborations with global partners, giving access to advanced technology, biosimilar drug substances and technical know-how, have further strengthened the company’s growth.
These partnerships have enabled Regenix to enter the markets at the right time, and improve its own innovation capabilities and global outlook at the same time.
Building Teams and Developing Future Talent
Dr Ramamurthy believes that in the end, innovation is people driven. This has resulted in Regenix establishing a culture of accountability, recognition, continuous learning and performance-based rewards.
The organization is dedicated to building scientific and leadership talent that can drive future growth and innovation.
Dr Ramamurthy also stresses the need for better synergy between educational institutions and industry to develop world class technical manpower for India’s burgeoning healthcare sector.
Building the Future of Healthcare for Everyone
“Moving forward, biosimilars will become one of the biggest growth drivers for the global pharmaceutical industry while dramatically enhancing patient access to advanced therapies,” says Dr Ramamurthy.
Increased access to technology platforms, scientific expertise and scalable manufacturing capabilities are pointing to the future of healthcare – affordable innovation at global quality standards.
The mission for Regenix remains clear – to use science, accessibility and affordability to improve the lives of millions across the world.
With global demand for affordable advanced therapies continuing to grow, companies like Regenix Drugs Ltd. are showing that meaningful healthcare innovation is not just about developing medicines – it’s about making them accessible to the people who need them most.
